gridegalutamide

**Gridegalutamide** is an oral, heterobifunctional androgen receptor ligand-directed degrader and competitive androgen receptor antagonist developed by Bristol Myers Squibb for prostate cancer. It recruits cereblon to drive ubiquitination and proteasomal degradation of wild-type and clinically relevant mutant androgen receptor while also competitively antagonizing residual androgen receptor signaling through the receptor ligand-binding domain. The asset is being evaluated in the phase 3 rechARge trial for metastatic castration-resistant prostate cancer and in a phase 2 neoadjuvant study with degarelix for high-risk localized prostate cancer before radical prostatectomy. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Gridegalutamide))

Other names

rechARge